Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 10/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12950570 | 0.83 | FGFR1 (0.39) | FGFR1SLC22A6EP300CYP2D6DNMT1 | |
| SCHEMBL23343373 | 0.82 | FGFR1 (0.44) | FGFR1SLC22A6EP300CYP2D6DNMT1 | |
| SCHEMBL1532184 | 0.78 | FGFR1 (0.42) | FGFR1SLC22A6EP300CYP2D6DNMT1 | |
| SCHEMBL12261276 | 0.76 | FGFR1 (0.47) | FGFR1SLC22A6EP300CYP2D6DNMT1 | |
| SCHEMBL20012082 | 0.76 | FGFR1 (0.41) | FGFR1SLC22A6EP300CYP2D6DNMT1 | |
| SCHEMBL19631097 | 0.76 | FGFR1 (0.45) | FGFR1SLC22A6EP300LMNA | |
| SCHEMBL13261399 | 0.75 | TLR8 (0.47) | FGFR1EP300 | |
| SCHEMBL15214234 | 0.75 | MAPT (0.52) | LMNA | |
| SCHEMBL13975422 | 0.74 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL27977634 | 0.74 | FGFR1 (0.48) | FGFR1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206827-A | Lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-8518885-B2 | Heterocyclic peptide ketoamides | GEORGIA TECH RESEARCH CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110053858-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| WO-2009099416-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053858-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | CAPNS1, CAPN1, CAPN2 | FGFR1 3737/4885SLC22A6 2645/4885EP300 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.